A recent study has identified mutations in the ubiquilin 2 gene in patients with dominant X-linked amyotrophic lateral sclerosis (ALS) and ALS–dementia. The results suggest that ubiquilin 2 inclusions and impairment of the protein degradation pathway contribute to the pathogenesis of ALS and possibly other neurodegenerative disorders.
This is a preview of subscription content, log in via an institution to check access.
References
Zinman, L. & Cudkowicz, M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 10, 481–490 (2011).
Strong, M. J. et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10, 131–146 (2009).
Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).
Kabashi, E. et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572–574 (2008).
Kwiatkowski, T. J. Jr et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208 (2009).
Deng, H. X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211–215 (2011).
Felbecker, A. et al. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? J. Neurol. Neurosurg. Psychiatry 81, 572–577 (2010).
Mackenzie, I. R., Rademakers, R. & Neumann, M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995–1007 (2010).
Petrucelli, L. & Dawson, T. M. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med. 36, 315–320 (2004).
Kabashi, E. & Durham, H. D. Failure of protein quality control in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1038–1050 (2006).
Acknowledgements
H. Daoud is supported by a postdoctoral fellowship from the ALS Society of Canada and the Canadian Institutes of Health Research. G. A. Rouleau holds a Canada Research Chair in Genetics of the Nervous System and the Jeanne et J-Louis-Lévesque Chair in Genetics of Brain Diseases.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Daoud, H., Rouleau, G. A role for ubiquilin 2 mutations in neurodegeneration. Nat Rev Neurol 7, 599–600 (2011). https://doi.org/10.1038/nrneurol.2011.163
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.163
- Springer Nature Limited
This article is cited by
-
Evaluation of Skin Fibroblasts from Amyotrophic Lateral Sclerosis Patients for the Rapid Study of Pathological Features
Neurotoxicity Research (2015)
-
Genetics of amyotrophic lateral sclerosis: an update
Molecular Neurodegeneration (2013)
-
Molecular evaluation of human Ubiquilin 2 gene PXX domain in familial frontotemporal dementia patients
Journal of Neurology (2012)